$NVAX
NOVAVAX INC Stock $nvax

$nvax Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000100069423000005 Filed on February 28, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$80.95M	$357.4M	$1.982B
YoY Change	-88.5%	60.85%	72.89%
Cost Of Revenue	$34.09M	$181.8M	$902.6M
YoY Change	124.19%
Gross Profit	$46.87M	$175.6M	$1.079B
YoY Change	-93.2%		-5.85%
Gross Profit Margin	57.89%	49.14%	54.46%
Selling, General & Admin	$112.5M	$161.7M	$488.7M
YoY Change	17.23%	91.97%	63.79%
% of Gross Profit	240.12%	92.05%	45.28%
Research & Development	$247.1M	$257.9M	$1.235B
YoY Change	-35.56%	-73.22%	-51.26%
% of Gross Profit	527.26%	146.81%	114.46%
Depreciation & Amortization	$9.043M	$7.222M	$29.10M
YoY Change	33.67%	96.68%	132.8%
% of Gross Profit	19.3%	4.11%	2.7%
Operating Expenses	$247.1M	$419.5M	$1.235B
YoY Change	-35.56%	-59.94%	-51.26%
Operating Profit	-$312.8M	-$243.9M	-$644.7M
YoY Change	-249.44%		-61.77%
Interest Expense	$4.316M	-$4.601M	$19.88M
YoY Change	-11.48%	-8.62%	-5.9%
% of Operating Profit
Other Income/Expense, Net	$24.36M	$63.97M	$10.97M
YoY Change	1372.91%	19226.59%	-233.82%
Pretax Income	-$292.7M	-$184.5M	-$653.6M
YoY Change	-242.05%	-77.76%	-61.88%
Income Tax	$1.183M	-$2.260M	$4.300M
% Of Pretax Income
Net Earnings	-$293.9M	-$182.2M	-$657.9M
YoY Change	-244.49%	-78.46%	-62.27%
Net Earnings / Revenue	-363.07%	-50.99%	-33.2%
Basic Earnings Per Share	-$3.41		-$8.42
Diluted Earnings Per Share	-$3.41	-$2.28	-$8.42
COMMON SHARES
Basic Shares Outstanding	86.17M shares	78.50M shares	78.18M shares
Diluted Shares Outstanding	86.16M shares		78.18M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$625.0M	$1.337B	$1.337B
YoY Change	-60.22%	-11.76%	-11.76%
Cash & Equivalents	$625.0M	$1.337B	$1.337B
Short-Term Investments
Other Short-Term Assets	$199.0M	$76.37M	$247.5M
YoY Change	3.86%	42.78%	33.75%
Inventory	$34.19M	$36.68M	$36.68M
Prepaid Expenses
Receivables	$112.8M	$82.38M	$82.38M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$971.0M	$1.703B	$1.703B
YoY Change	-58.63%	-20.96%	-20.96%
LONG-TERM ASSETS
Property, Plant & Equipment	$307.4M	$294.2M	$400.5M
YoY Change	24.35%	28.66%	48.98%
Goodwill	$129.8M	$126.3M
YoY Change	-0.71%	-3.92%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$30.51M	$28.47M	$28.47M
YoY Change	63.89%	71.85%	71.85%
Total Long-Term Assets	$571.7M	$555.3M	$555.3M
YoY Change	17.27%	31.7%	31.7%
TOTAL ASSETS
Total Short-Term Assets	$971.0M	$1.703B	$1.703B
Total Long-Term Assets	$571.7M	$555.3M	$555.3M
Total Assets	$1.543B	$2.259B	$2.259B
YoY Change	-45.58%	-12.34%	-12.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$124.8M	$216.5M	$216.5M
YoY Change	-7.64%	70.42%	70.42%
Accrued Expenses	$518.7M	$591.2M	$608.0M
YoY Change	-7.35%	-12.26%	-13.72%
Deferred Revenue	$415.8M	$400.0M
YoY Change	-62.2%	-71.43%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%
Long-Term Debt Due	$1.205M	$352.1M	$352.1M
YoY Change	-98.97%	169.72%	169.72%
Total Short-Term Liabilities	$1.919B	$2.460B	$2.460B
YoY Change	-15.13%	2.91%	2.91%
LONG-TERM LIABILITIES
Long-Term Debt	$197.9M	$197.7M	$197.7M
YoY Change		-38.88%	-38.88%
Other Long-Term Liabilities	$47.51M	$55.70M	$235.1M
YoY Change	-28.87%	32.23%	9.53%
Total Long-Term Liabilities	$47.51M	$55.70M	$432.8M
YoY Change	-28.87%	32.23%	-19.57%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.919B	$2.460B	$2.460B
Total Long-Term Liabilities	$47.51M	$55.70M	$432.8M
Total Liabilities	$2.438B	$2.893B	$2.893B
YoY Change	-11.96%	-1.22%	-1.22%
SHAREHOLDERS EQUITY
Retained Earnings	-$4.570B	-$4.276B
YoY Change	33.83%	18.19%
Common Stock	$871.0K	$868.0K
YoY Change	10.67%	13.61%
Preferred Stock
YoY Change
Treasury Stock (at cost)		$90.66M
YoY Change		6.53%
Treasury Stock Shares		766.6K shares
Shareholders Equity	-$895.6M	-$634.1M	-$634.1M
YoY Change
Total Liabilities & Shareholders Equity	$1.543B	$2.259B	$2.259B
YoY Change	-45.58%	-12.34%	-12.34%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$293.9M	-$182.2M	-$657.9M
YoY Change	-244.49%	-78.46%	-62.27%
Depreciation, Depletion And Amortization	$9.043M	$7.222M	$29.10M
YoY Change	33.67%	96.68%	132.8%
Cash From Operating Activities	-$325.6M	-$117.8M	-$415.9M
YoY Change	267.87%	-65.59%	-228.78%
INVESTING ACTIVITIES
Capital Expenditures	$19.80M	$22.06M	$92.99M
YoY Change	-217.68%	-234.83%	-261.75%
Acquisitions			$0.00
YoY Change
Other Investing Activities	-$3.757M	$0.00	$0.00
YoY Change			-100.0%
Cash From Investing Activities	-$23.56M	-$22.06M	-$92.99M
YoY Change	40.01%	34.83%	-192.84%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$249.2M
YoY Change			-55.88%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$354.4M	191.4M	$325.0M
YoY Change	-321.67%	-415.33%	-29.61%
NET CHANGE
Cash From Operating Activities	-$325.6M	-117.8M	-$415.9M
Cash From Investing Activities	-$23.56M	-22.06M	-$92.99M
Cash From Financing Activities	-$354.4M	191.4M	$325.0M
Net Change In Cash	-$711.9M	51.56M	-$179.4M
YoY Change	-1374.87%	-112.29%	-120.4%
FREE CASH FLOW
Cash From Operating Activities	-$325.6M	-$117.8M	-$415.9M
Capital Expenditures	$19.80M	$22.06M	$92.99M
Free Cash Flow	-$345.4M	-$139.9M	-$508.9M
YoY Change	381.84%	-57.1%	-233.77%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001000694
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://www.novavax.com/20221231#LeaseRightOfUseAsset
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://www.novavax.com/20221231#LeaseRightOfUseAsset
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://www.novavax.com/20221231#LeaseRightOfUseAsset
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://www.novavax.com/20221231#LeaseRightOfUseAsset
CY2022	dei	City Area Code CityAreaCode	(240)
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	000-26770
CY2022	dei	Entity Registrant Name EntityRegistrantName	NOVAVAX, INC
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	22-2816046
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	21 Firstfield Road,
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Gaithersburg,
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20878
CY2022	dei	Local Phone Number LocalPhoneNumber	268-2000
CY2022	dei	Security12b Title Security12bTitle	Common Stock, Par Value $0.01 per share
CY2022	dei	Trading Symbol TradingSymbol	NVAX
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	false
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	4010000000	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	86173245	shares
CY2022	dei	Auditor Firm AuditorFirmId	42
CY2022	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2022	dei	Auditor Location AuditorLocation	Tysons, Virginia
CY2022	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2022	dei	Auditor Location AuditorLocation	Tysons, Virginia
CY2022	us-gaap	Revenues Revenues	1981872000	usd
CY2021	us-gaap	Revenues Revenues	1146290000	usd
CY2020	us-gaap	Revenues Revenues	475598000	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	902639000	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	0	usd
CY2020	us-gaap	Cost Of Revenue CostOfRevenue	0	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1235278000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2534508000	usd
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	747027000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	488691000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	298358000	usd
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	145290000	usd
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	2626608000	usd
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	2832866000	usd
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	892317000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-644736000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-1686576000	usd
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-416719000	usd
CY2022	us-gaap	Interest Expense InterestExpense	19880000	usd
CY2021	us-gaap	Interest Expense InterestExpense	21127000	usd
CY2020	us-gaap	Interest Expense InterestExpense	15145000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	10969000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-6833000	usd
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	13605000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-653647000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1714536000	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-418259000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4292000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	29215000	usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-657939000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-1743751000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-418259000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-8.42
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-8.42
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-23.44
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-23.44
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-7.27
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-7.27
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	78183000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	78183000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	74400000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	74400000	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	57554000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	57554000	shares
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-657939000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-1743751000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-418259000	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	usd
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-9000	usd
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	9000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-5024000	usd
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-8368000	usd
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	19523000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-5024000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-8377000	usd
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	19532000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-662963000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1752128000	usd
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-398727000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1336883000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1515116000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	10303000	usd
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	11490000	usd
CY2022Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	82375000	usd
CY2021Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	454993000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	36683000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	8872000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	237147000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	164648000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1703391000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	2155119000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	294247000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	225741000	usd
CY2022Q4	nvax	Lease Right Of Use Asset LeaseRightOfUseAsset	106241000	usd
CY2021Q4	nvax	Lease Right Of Use Asset LeaseRightOfUseAsset	40123000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	126331000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	131479000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	28469000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	24291000	usd
CY2022Q4	us-gaap	Assets Assets	2258679000	usd
CY2021Q4	us-gaap	Assets Assets	2576753000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	216517000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	127050000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	591158000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	673731000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	370137000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1422944000	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	27196000	usd
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	130533000	usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	324881000	usd
CY2021Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	0	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	930055000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	36061000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2459944000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2390319000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	179414000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	172528000	usd
CY2022Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	166466000	usd
CY2021Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	323458000	usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	31238000	usd
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	0	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	55695000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	42121000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	2892757000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	2928426000	usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	600000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	600000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	86806554	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	86039923	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	76433151	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	75841171	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	868000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	764000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3737979000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3351967000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4275889000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-3617950000	usd
CY2022Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	766631	shares
CY2021Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	591980	shares
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	90659000	usd
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	85101000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-6377000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1353000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-634078000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-351673000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2258679000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2576753000	usd
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-186017000	usd
CY2020	nvax	Stock Issued During Period Value Preferred Stock Beneficial Conversion Increase Decrease StockIssuedDuringPeriodValuePreferredStockBeneficialConversionIncreaseDecrease	0	usd
CY2020	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	199822000	usd
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	128035000	usd
CY2020	nvax	Compensation Stock Issued Under Incentive Program CompensationStockIssuedUnderIncentiveProgram	5246000	usd
CY2020	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	11416000	usd
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	878850000	usd
CY2020	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	9000	usd
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	19523000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-418259000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	627209000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	183626000	usd
CY2021	nvax	Compensation Stock Issued Under Incentive Program CompensationStockIssuedUnderIncentiveProgram	24761000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	7292000	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	564859000	usd
CY2021	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-9000	usd
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-8368000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-1743751000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-351673000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	131967000	usd
CY2022	nvax	Compensation Stock Issued Under Incentive Program CompensationStockIssuedUnderIncentiveProgram	-639000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	7216000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	249230000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-5024000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-657939000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-634078000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-657939000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-1743751000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-418259000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	29054000	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	12661000	usd
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4885000	usd
CY2022	nvax	Operating And Finance Lease Write Off OperatingAndFinanceLeaseWriteOff	18104000	usd
CY2021	nvax	Operating And Finance Lease Write Off OperatingAndFinanceLeaseWriteOff	144433000	usd
CY2020	nvax	Operating And Finance Lease Write Off OperatingAndFinanceLeaseWriteOff	245861000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	130300000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	183626000	usd
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	128035000	usd
CY2022	nvax	Provision For Excess And Obsolete Inventory ProvisionForExcessAndObsoleteInventory	447597000	usd
CY2021	nvax	Provision For Excess And Obsolete Inventory ProvisionForExcessAndObsoleteInventory	0	usd
CY2020	nvax	Provision For Excess And Obsolete Inventory ProvisionForExcessAndObsoleteInventory	0	usd
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	21903000	usd
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	7641000	usd
CY2020	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	15080000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	477801000	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	8872000	usd
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-249166000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	183393000	usd
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	422689000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	913399000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	600326000	usd
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	163161000	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1045914000	usd
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	1325557000	usd
CY2020	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	271545000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-415937000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	322946000	usd
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-42541000	usd
CY2022	us-gaap	Payments For Capital Improvements PaymentsForCapitalImprovements	89056000	usd
CY2021	us-gaap	Payments For Capital Improvements PaymentsForCapitalImprovements	54501000	usd
CY2020	us-gaap	Payments For Capital Improvements PaymentsForCapitalImprovements	54473000	usd
CY2022	us-gaap	Payments For Software PaymentsForSoftware	3929000	usd
CY2021	us-gaap	Payments For Software PaymentsForSoftware	2985000	usd
CY2020	us-gaap	Payments For Software PaymentsForSoftware	149000	usd
CY2022	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	usd
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	usd
CY2020	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	165516000	usd
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	usd
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	2167000	usd
CY2020	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	363202000	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	0	usd
CY2021	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	159807000	usd
CY2020	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	205562000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-92985000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	100154000	usd
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-377778000	usd
CY2022	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	usd
CY2021	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	usd
CY2020	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	199822000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	249230000	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	564859000	usd
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	875623000	usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	175250000	usd
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	usd
CY2020	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	usd
CY2022	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	5258000	usd
CY2021	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	usd
CY2020	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	usd
CY2022	nvax	Net Proceeds From The Exercise Of Stock Based Awards NetProceedsFromTheExerciseOfStockBasedAwards	-639000	usd
CY2021	nvax	Net Proceeds From The Exercise Of Stock Based Awards NetProceedsFromTheExerciseOfStockBasedAwards	24761000	usd
CY2020	nvax	Net Proceeds From The Exercise Of Stock Based Awards NetProceedsFromTheExerciseOfStockBasedAwards	5382000	usd
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	93595000	usd
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	127907000	usd
CY2020	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	96065000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	324988000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	461713000	usd
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	984762000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4520000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-5292000	usd
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2115000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-179414000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	879521000	usd
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	566558000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1528259000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	648738000	usd
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	82180000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1348845000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1528259000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	648738000	usd
CY2022	nvax	Proceeds From Issuance Or Sale Of Equity Not Settled ProceedsFromIssuanceOrSaleOfEquityNotSettled	0	usd
CY2021	nvax	Proceeds From Issuance Or Sale Of Equity Not Settled ProceedsFromIssuanceOrSaleOfEquityNotSettled	0	usd
CY2020	nvax	Proceeds From Issuance Or Sale Of Equity Not Settled ProceedsFromIssuanceOrSaleOfEquityNotSettled	3227000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	17665000	usd
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	10338000	usd
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	9255000	usd
CY2022	nvax	Non Cash Related Transactions For Finance Lease Right Of Use Asset NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset	91855000	usd
CY2021	nvax	Non Cash Related Transactions For Finance Lease Right Of Use Asset NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset	179210000	usd
CY2020	nvax	Non Cash Related Transactions For Finance Lease Right Of Use Asset NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset	247599000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	18035000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	19428000	usd
CY2020	us-gaap	Interest Paid Net InterestPaidNet	13705000	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	17980000	usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	12606000	usd
CY2020	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2022	us-gaap	Nature Of Operations NatureOfOperations	Organization<div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novavax, Inc. (“Novavax,” and together with its wholly owned subsidiaries, the “Company”) is a biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. The Company’s COVID-19 vaccine NVX-CoV2373 (“Nuvaxovid™,” “Covovax™,” “Novavax COVID-19 Vaccine, Adjuvanted”); influenza vaccine candidate; COVID-19-Influenza Combination (“CIC”) vaccine candidate; and additional vaccine candidates, including for Omicron subvariants and bivalent formulations with prototype vaccine (“NVX-CoV2373”), are genetically engineered nanostructures of conformationally correct recombinant proteins critical to disease pathogenesis and may elicit differentiated immune responses, which may be more efficacious than naturally occurring immunity or other vaccine approaches. NVX-CoV2373 and the Company’s other vaccine candidates incorporate the Company's proprietary Matrix-M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response. The Company has announced data from its ongoing PREVENT-19 study supporting the use of NVX-CoV2373 for homologous boosting in adults and adolescents aged 12 through 17. Additional findings in Phase 3 COVID-19 Omicron (study 311) trial showed utility of the prototype vaccine as a heterologous booster, inducing broad immune responses against contemporary Omicron variants.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the Company had received approval, interim authorization, provisional approval, conditional marketing authorization, and emergency use authorization (“EUA”) from multiple regulatory authorities globally for NVX-CoV2373 for both adult and adolescent populations as a primary series and for both homologous and heterologous booster indications.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company commenced commercial shipments of NVX-CoV2373 doses under the name “Novavax COVID-19 Vaccine, Adjuvanted” and the brand name “Nuvaxovid™” in 2022.</span></div>
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1300000000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-657900000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-415900000	usd
CY2022	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain amounts reported in prior periods have been reclassified to conform to current period financial statement presentation. These reclassifications have no material effect on previously reported financial position, cash flows, or results of operations.</span></div>
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with generally accepted accounting principles in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Estimates are used for, but not limited to, revenue recognition, inventory, research and development expenses, stock-based compensation, useful lives of long-lived assets, leases, and income taxes. Actual results could differ materially from those estimates.</span></div>
CY2022	us-gaap	Advertising Expense AdvertisingExpense	84000000	usd
CY2021	us-gaap	Advertising Expense AdvertisingExpense	8900000	usd
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risk</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments expose the Company to concentration of credit risk and consist primarily of cash and cash equivalents. The Company’s investment policy limits investments to certain types of instruments, including asset-backed securities, high-grade corporate debt securities, and money market funds; places restrictions on maturities and concentrations in certain industries; and requires the Company to maintain a certain level of liquidity. At times, the Company maintains cash balances in financial institutions that may exceed federally insured limits. The Company has not experienced any losses relating to such accounts and believes it is not exposed to a significant credit risk on its cash and cash equivalents.</span></div>The Company currently depends exclusively on a single supplier for co-formulation, filling, and finishing NVX-CoV2373. The loss of this supplier could prevent or delay the Company’s delivery of customer orders.
CY2022	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1	reporting_unit
CY2021Q4	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2022Q4	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4300000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	29200000	usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-6400000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-1400000	usd
CY2022	us-gaap	Translation Adjustment Functional To Reporting Currency Gain Loss Reclassified To Earnings Net Of Tax TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax	-2500000	usd
CY2021	us-gaap	Translation Adjustment Functional To Reporting Currency Gain Loss Reclassified To Earnings Net Of Tax TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax	-5300000	usd
CY2020	us-gaap	Translation Adjustment Functional To Reporting Currency Gain Loss Reclassified To Earnings Net Of Tax TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax	9600000	usd
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2022Q4	us-gaap	Billed Contract Receivables BilledContractReceivables	53800000	usd
CY2021Q4	us-gaap	Billed Contract Receivables BilledContractReceivables	419700000	usd
CY2022Q4	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	28600000	usd
CY2021Q4	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	35300000	usd
CY2021Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	454993000	usd
CY2022	nvax	Accounts Receivable Before Allowance For Credit Loss Additions AccountsReceivableBeforeAllowanceForCreditLossAdditions	1768457000	usd
CY2022	nvax	Accounts Receivable Before Allowance For Credit Loss Deductions AccountsReceivableBeforeAllowanceForCreditLossDeductions	2127240000	usd
CY2022Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	96210000	usd
CY2020Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	262012000	usd
CY2021	nvax	Accounts Receivable Before Allowance For Credit Loss Additions AccountsReceivableBeforeAllowanceForCreditLossAdditions	2432268000	usd
CY2021	nvax	Accounts Receivable Before Allowance For Credit Loss Deductions AccountsReceivableBeforeAllowanceForCreditLossDeductions	2239287000	usd
CY2021Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	454993000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2022	nvax	Accounts Receivable Allowance For Credit Loss Additions AccountsReceivableAllowanceForCreditLossAdditions	13835000	usd
CY2022	nvax	Accounts Receivable Allowance For Credit Loss Deductions AccountsReceivableAllowanceForCreditLossDeductions	0	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	13835000	usd
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2021	nvax	Accounts Receivable Allowance For Credit Loss Additions AccountsReceivableAllowanceForCreditLossAdditions	0	usd
CY2021	nvax	Accounts Receivable Allowance For Credit Loss Deductions AccountsReceivableAllowanceForCreditLossDeductions	0	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	1595472000	usd
CY2022	nvax	Contract With Customer Liability Additions ContractWithCustomerLiabilityAdditions	46908000	usd
CY2022	nvax	Contract With Customer Liability Deductions ContractWithCustomerLiabilityDeductions	1092829000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	549551000	usd
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	273228000	usd
CY2021	nvax	Contract With Customer Liability Additions ContractWithCustomerLiabilityAdditions	1598152000	usd
CY2021	nvax	Contract With Customer Liability Deductions ContractWithCustomerLiabilityDeductions	275908000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1659000	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	1595472000	usd
CY2022	nvax	Accounts Receivable Allowance For Credit Loss Additions AccountsReceivableAllowanceForCreditLossAdditions	13800000	usd
CY2021	nvax	Accounts Receivable Allowance For Credit Loss Additions AccountsReceivableAllowanceForCreditLossAdditions	0	usd
CY2020	nvax	Accounts Receivable Allowance For Credit Loss Additions AccountsReceivableAllowanceForCreditLossAdditions	0	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	400000000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1400000000	usd
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	300000000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	179400000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	172500000	usd
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	0	usd
CY2022Q4	nvax	Collaboration Agreement Upfront Payment Amount CollaborationAgreementUpfrontPaymentAmount	819000000	usd
CY2022Q4	nvax	Revenue Performance Obligation Satisfied At Point In Time Amount RevenuePerformanceObligationSatisfiedAtPointInTimeAmount	41900000	usd
CY2022Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	3000000000	usd
CY2022Q4	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2020Q4	nvax	Purchase Agreement Number Of Vaccine Doses PurchaseAgreementNumberOfVaccineDoses	60000000	dose
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1336883000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1515116000	usd
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	553398000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	10303000	usd
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	11490000	usd
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	93880000	usd
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1653000	usd
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1460000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1348845000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1528259000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	648738000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	13912000	usd
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	8872000	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	21410000	usd
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	0	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1361000	usd
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	0	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	36683000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	8872000	usd
CY2022	nvax	Inventory Reserve Charged To Costs Of Sales InventoryReserveChargedToCostsOfSales	447600000	usd
CY2022	us-gaap	Inventory Firm Purchase Commitment Loss InventoryFirmPurchaseCommitmentLoss	155900000	usd
CY2021	us-gaap	Inventory Firm Purchase Commitment Loss InventoryFirmPurchaseCommitmentLoss	0	usd
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
CY2020	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
CY2020	us-gaap	Inventory Firm Purchase Commitment Loss InventoryFirmPurchaseCommitmentLoss	0	usd
CY2021Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	0	usd
CY2022	nvax	Inventory Reserve Charged To Costs Of Sales InventoryReserveChargedToCostsOfSales	447597000	usd
CY2022	nvax	Inventory Reserve Other Additions InventoryReserveOtherAdditions	0	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	-79214000	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	368383000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	131479000	usd
CY2020Q4	us-gaap	Goodwill Goodwill	135379000	usd
CY2022	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-5148000	usd
CY2021	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-3900000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	126331000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	131479000	usd
CY2020	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	475598000	usd
CY2020	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-419896000	usd
CY2020	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	-7.04
CY2020	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	-7.04
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	36384000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	40123000	usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	69857000	usd
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	0	usd
CY2022Q4	nvax	Lease Right Of Use Asset LeaseRightOfUseAsset	106241000	usd
CY2021Q4	nvax	Lease Right Of Use Asset LeaseRightOfUseAsset	40123000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	16867000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	30983000	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	27196000	usd
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	130533000	usd
CY2022Q4	nvax	Lease Liability Current LeaseLiabilityCurrent	44063000	usd
CY2021Q4	nvax	Lease Liability Current LeaseLiabilityCurrent	161516000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	50085000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	39116000	usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	31238000	usd
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	0	usd
CY2022Q4	nvax	Lease Liability Noncurrent LeaseLiabilityNoncurrent	81323000	usd
CY2021Q4	nvax	Lease Liability Noncurrent LeaseLiabilityNoncurrent	39116000	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y7M6D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y
CY2022Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P8Y3M18D
CY2021Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P3Y8M12D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.064
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.060
CY2022Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.054
CY2021Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.052
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	6903000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	37027000	usd
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	2462000	usd
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	94726000	usd
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	468210000	usd
CY2020	us-gaap	Short Term Lease Cost ShortTermLeaseCost	66805000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	6836000	usd
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	116435000	usd
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	4854000	usd
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	7759000	usd
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	112528000	usd
CY2020	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	242009000	usd
CY2022	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	1472000	usd
CY2021	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	7241000	usd
CY2020	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	3097000	usd
CY2022	us-gaap	Lease Cost LeaseCost	9231000	usd
CY2021	us-gaap	Lease Cost LeaseCost	119769000	usd
CY2020	us-gaap	Lease Cost LeaseCost	245106000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	190158000	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	203991000	usd
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	63634000	usd
CY2022	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	1472000	usd
CY2021	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	7241000	usd
CY2020	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	3097000	usd
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	93595000	usd
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	127907000	usd
CY2020	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	96065000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	30675000	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	66682000	usd
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	5590000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	73240000	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	112528000	usd
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	242009000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	47335000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	24589000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	10446000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	10509000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	10250000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	46562000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	149691000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	24305000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	125386000	usd
CY2022Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	119000	usd
CY2021Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	0	usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	324881000	usd
CY2021Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	0	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	8784000	usd
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	1542000	usd
CY2022Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	166466000	usd
CY2021Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	323458000	usd
CY2022	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	12542000	usd
CY2021	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	12188000	usd
CY2020	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	12188000	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1497000	usd
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1424000	usd
CY2020	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1424000	usd
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt	14039000	usd
CY2021	us-gaap	Interest Expense Debt InterestExpenseDebt	13612000	usd
CY2020	us-gaap	Interest Expense Debt InterestExpenseDebt	13612000	usd
CY2020Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	455.70
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	130300000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	183626000	usd
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	128035000	usd
CY2022	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	1700000	usd
CY2021	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	0	usd
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	171000000	usd
CY2022	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y1M6D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	21400000	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	453800000	usd
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	187300000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	3000000	usd
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y1M6D
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	2000000	usd
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y7M6D
CY2022	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	1
CY2022	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.04
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	6000000	usd
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	3400000	usd
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	900000	usd
CY2022Q4	us-gaap	Supplies Supplies	160773000	usd
CY2021Q4	us-gaap	Supplies Supplies	120029000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	76374000	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	44619000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	237147000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	164648000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	341539000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	251540000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	47292000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	25799000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	294247000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	225741000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	29100000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	12500000	usd
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4300000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	52569000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	38419000	usd
CY2022Q4	nvax	Research And Development Accruals ResearchAndDevelopmentAccruals	468214000	usd
CY2021Q4	nvax	Research And Development Accruals ResearchAndDevelopmentAccruals	577100000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	70375000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	58212000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	591158000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	673731000	usd
CY2022Q4	us-gaap	Customer Refund Liability Current CustomerRefundLiabilityCurrent	210362000	usd
CY2021Q4	us-gaap	Customer Refund Liability Current CustomerRefundLiabilityCurrent	0	usd
CY2022Q4	nvax	Other Current Liability Related To Advance Purchase Agreements OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements	697384000	usd
CY2021Q4	nvax	Other Current Liability Related To Advance Purchase Agreements OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements	0	usd
CY2022Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	22309000	usd
CY2021Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	36061000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	930055000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	36061000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-712183000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-1633016000	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-455253000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	58536000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-81520000	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	36994000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-653647000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1714536000	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-418259000	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	1300000	usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	503000	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	2489000	usd
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	29215000	usd
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	4292000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	29215000	usd
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	4300000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	29200000	usd
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.02
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.06
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.03
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.01
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.01
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.01
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.02
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.04
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.01
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0.04
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0.07
CY2022	nvax	Effective Income Tax Rate Reconciliation Us Taxation Of Foreign Operations EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations	-0.03
CY2021	nvax	Effective Income Tax Rate Reconciliation Us Taxation Of Foreign Operations EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations	0
CY2020	nvax	Effective Income Tax Rate Reconciliation Us Taxation Of Foreign Operations EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.01
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.02
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.01
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.01
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.20
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.05
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.02
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.30
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.31
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.01
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.02
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	479134000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	845731000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	5752000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	25625000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	45560000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	44618000	usd
CY2022Q4	nvax	Deferred Tax Asset Leasing Liability DeferredTaxAssetLeasingLiability	27625000	usd
CY2021Q4	nvax	Deferred Tax Asset Leasing Liability DeferredTaxAssetLeasingLiability	52852000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	195049000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	20262000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	213076000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	27599000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	24698000	usd
CY2022Q4	nvax	Deferred Tax Assets Original Discount Interest DeferredTaxAssetsOriginalDiscountInterest	0	usd
CY2021Q4	nvax	Deferred Tax Assets Original Discount Interest DeferredTaxAssetsOriginalDiscountInterest	1729000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	49309000	usd
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	13695000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	11801000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1056799000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1027316000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1020123000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1015333000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	36676000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	11983000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	23330000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	10071000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	11587000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	0	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	1055000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	1034000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	704000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	878000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	36676000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	11983000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	4800000	usd
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	510500000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1100000000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1000000000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	11154000	usd
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	8766000	usd
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1260000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	4158000	usd
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1413000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	807000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	7353000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	8027000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	1770000	usd
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities	0	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities	0	usd
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5194000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	11154000	usd
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	8766000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	5200000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	11200000	usd
CY2022Q4	us-gaap	Loss Contingency Number Of Defendants LossContingencyNumberOfDefendants	2	defendant
CY2022Q4	nvax	Loss Contingency Period To Answer LossContingencyPeriodToAnswer	P14D
CY2021Q3	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	1500000	usd
CY2022Q4	us-gaap	Purchase Obligation PurchaseObligation	0	usd

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
nvax-20221231_cal.xml	Edgar Link	unprocessable
0001000694-23-000005-index-headers.html	Edgar Link	pending
0001000694-23-000005-index.html	Edgar Link	pending
0001000694-23-000005.txt	Edgar Link	pending
0001000694-23-000005-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_0.jpg	Edgar Link	pending
image_01.jpg	Edgar Link	pending
image_02.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nvax-20221231.htm	Edgar Link	pending
nvax-20221231.xsd	Edgar Link	pending
nvax-20221231xex1018.htm	Edgar Link	pending
nvax-20221231xex1020.htm	Edgar Link	pending
nvax-20221231xex1056.htm	Edgar Link	pending
nvax-20221231xex21.htm	Edgar Link	pending
nvax-20221231xex231.htm	Edgar Link	pending
nvax-20221231xex311.htm	Edgar Link	pending
nvax-20221231xex312.htm	Edgar Link	pending
nvax-20221231xex321.htm	Edgar Link	pending
nvax-20221231xex322.htm	Edgar Link	pending
nvax-20221231xex44.htm	Edgar Link	pending
nvax-20221231_g1.jpg	Edgar Link	pending
nvax-20221231_g2.jpg	Edgar Link	pending
nvax-20221231_g3.jpg	Edgar Link	pending
nvax-20221231_def.xml	Edgar Link	unprocessable
nvax-20221231_pre.xml	Edgar Link	unprocessable
nvax-20221231_lab.xml	Edgar Link	unprocessable
nvax-20221231_htm.xml	Edgar Link	completed
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NVAX
NOVAVAX INC Stock $nvax

2023 Q1 Form 10-K Financial Statement

#000100069423000005 Filed on February 28, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NVAX NOVAVAX INC Stock $nvax

2023 Q1 Form 10-K Financial Statement

#000100069423000005 Filed on February 28, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NVAX
NOVAVAX INC Stock $nvax